ArticleFrontiers in bioengineering and biotechnology2026
C-1101 multi-protein platelet and plasma-derived therapeutic to treat chronic lumbosacral radiculopathy.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Intervertebral disc disease (IVDD) leads to chronic lumbosacral radiculopathy (LSR) with nerve root compression resulting in numbness and low back pain. The aim was to evaluate therapeutic and immunomodulatory potential of multi-protein platelet and plasma-derived biologic (C-1101) to alter inflammatory mediators and gene expression in IVDD. Methods: In aim 1, intervertebral discs and dorsal root ganglia (DRG) were harvested from female ovine lumbar spines (n = 6). Annulus fibrosus (AF), nucleus pulposus (NP) and DRG were dissociated to form single-cell suspensions. Cells were plated (100,000 cells/well, 24-well plates) and subjected to 4 treatments, 24 h (non-stimulated, IL-1β+TNF-α, IL-1β+TNF-α+C-1101, IL-1β+TNF-α+vehicle). Cells were washed, cultured 24 h, and media evaluated for cytokine secretion (n = 14) by ovine multiplex immunoassay. mRNA was collected from cells and sequencing performed via Illumina-based platform. In aim 2, peripheral neuropathy was induced (paclitaxel) in male C57Bl6/J mice who were treated intravenously with C-1101 or vehicle. Mice were assessed via acetone cooling for allodynia and plasma evaluated for cytokines. Results: C-1101 elicited cytokine release from ovine AF and NP cells but not DRG. Gene expression analyses revealed upregulation of cell replication and translation pathways but downregulation of inflammatory (namely, interferons), extracellular matrix and cell signaling pathways in AF/NP, with upregulation of translation and ribosome activity in DRG. C-1101 reduced allodynia and transiently induced elevated plasma IL-1β in murine peripheral neuropathy. Discussion: Functional reduction in pain sensation with C-1101 was observed in murine peripheral neuropathy, indicating potential therapeutic efficacy. C-1101 induced a mixed inflammatory response in cultured cells, warranting further investigation of mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.